申请人:Mead Johnson & Company
公开号:US04414213A1
公开(公告)日:1983-11-08
A series of 1,4-dihydropyrid-5-yl cyclic imidate esters have been prepared possessing the general formula ##STR1## wherein R and R.sup.1 are independently selected from hydrogen, lower alkyl or alkoxyalkyl groups; R.sup.2 is lower alkyl, aryl, or hetaryl; R.sup.3 is cycloalkyl, aryl or hetaryl, generally with electron-withdrawing substituents; R.sup.4 is lower alkyl, alkoxyalkyl, aminoalkyl, haloalkyl, or dialkylaminoalkyl; R.sup.5 is lower alkyl or aryl; m is 0 or 1; and n is 0, 1, or 2. Compounds of this series demonstrate blockage of calcium ion flux in tissue preparations in vitro and vasodilation in animal testing in vivo.
已制备一系列具有一般式##STR1##的1,4-二氢吡啶-5-基环酰亚胺酯,其中R和R.sup.1独立选择自氢、较低的烷基或烷氧基烷基基团;R.sup.2是较低的烷基、芳基或杂环基;R.sup.3是环烷基、芳基或杂环基,通常带有吸电子取代基;R.sup.4是较低的烷基、烷氧基烷基、氨基烷基、卤代烷基或二烷基氨基烷基;R.sup.5是较低的烷基或芳基;m为0或1;n为0、1或2。该系列化合物在体外组织制备中表现出对钙离子通量的阻断作用,并在动物体内测试中表现出血管舒张作用。